These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 25361998)

  • 1. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma.
    Marie-Cardine A; Viaud N; Thonnart N; Joly R; Chanteux S; Gauthier L; Bonnafous C; Rossi B; Bléry M; Paturel C; Bensussan A; Bagot M; Sicard H
    Cancer Res; 2014 Nov; 74(21):6060-70. PubMed ID: 25361998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma.
    Van Der Weyden C; Bagot M; Neeson P; Darcy PK; Prince HM
    Expert Opin Investig Drugs; 2018 Aug; 27(8):691-697. PubMed ID: 30001170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
    Bagot M; Porcu P; Marie-Cardine A; Battistella M; William BM; Vermeer M; Whittaker S; Rotolo F; Ram-Wolff C; Khodadoust MS; Bensussan A; Paturel C; Bonnafous C; Sicard H; Azim HA; Kim YH
    Lancet Oncol; 2019 Aug; 20(8):1160-1170. PubMed ID: 31253572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.
    Battistella M; Janin A; Jean-Louis F; Collomb C; Leboeuf C; Sicard H; Bonnafous C; Dujardin A; Ram-Wolff C; Kadin ME; Bensussan A; Bagot M; Michel L
    Br J Dermatol; 2016 Aug; 175(2):325-33. PubMed ID: 27037558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Targeted Treatments for Cutaneous T-cell Lymphomas.
    Bagot M
    Indian J Dermatol; 2017; 62(2):142-145. PubMed ID: 28400633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Epidermotropic T cell lymphomas as models for tumor progression].
    Bagot M; Bensussan A
    Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
    Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
    J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients.
    Bouaziz JD; Ortonne N; Giustiniani J; Schiavon V; Huet D; Bagot M; Bensussan A
    J Invest Dermatol; 2005 Dec; 125(6):1273-8. PubMed ID: 16354199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas.
    Schmitt C; Marie-Cardine A; Bensussan A
    Front Immunol; 2017; 8():1010. PubMed ID: 28912774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
    Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells.
    Chang DK; Sui J; Geng S; Muvaffak A; Bai M; Fuhlbrigge RC; Lo A; Yammanuru A; Hubbard L; Sheehan J; Campbell JJ; Zhu Q; Kupper TS; Marasco WA
    Mol Cancer Ther; 2012 Nov; 11(11):2451-61. PubMed ID: 22869555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.
    Sicard H; Bonnafous C; Morel A; Bagot M; Bensussan A; Marie-Cardine A
    Oncoimmunology; 2015 Sep; 4(9):e1022306. PubMed ID: 26405593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.
    Ishii T; Ishida T; Utsunomiya A; Inagaki A; Yano H; Komatsu H; Iida S; Imada K; Uchiyama T; Akinaga S; Shitara K; Ueda R
    Clin Cancer Res; 2010 Mar; 16(5):1520-31. PubMed ID: 20160057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.
    Wechsler J; Bagot M; Nikolova M; Parolini S; Martin-Garcia N; Boumsell L; Moretta A; Bensussan A
    J Pathol; 2003 Jan; 199(1):77-83. PubMed ID: 12474229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells.
    Amatore F; Ortonne N; Lopez M; Orlanducci F; Castellano R; Ingen-Housz-Oro S; De Croos A; Salvado C; Gorvel L; Goubard A; Collette Y; Bouabdallah R; Schiano JM; Bonnet N; Grob JJ; Gaulard P; Bagot M; Bensussan A; Berbis P; Olive D
    Blood Adv; 2020 Oct; 4(20):5203-5214. PubMed ID: 33095875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism.
    Adams S; Miller GT; Jesson MI; Watanabe T; Jones B; Wallner BP
    Cancer Res; 2004 Aug; 64(15):5471-80. PubMed ID: 15289357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma with KIR3DL2 and NKp46 expression in a human immunodeficiency virus carrier.
    Karkouche R; Ingen-Housz-Oro S; Le Gouvello S; Charlotte F; Thomas M; Zehou O; Frenkel V; Boutboul D; Chosidow O; Caumes E; Gaulard P; Ortonne N
    J Cutan Pathol; 2015 Mar; 42(3):199-205. PubMed ID: 25407699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.